Delivery systems: a vaccine strategy for overcoming mucosal tolerance?

V.A. Ferro, J.F.S. Mann, R. Acevedo, J. del Campo, O. Pere

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Antigens administered via the oral and, to a lesser extent, the nasal route are potentially able to invoke tolerance, resulting in a nonreactive immune response. This has been a hurdle for mucosal vaccine development and yet the desire to induce protective local and systemic responses, with pain-free and more convenient products, has been the impetus driving mucosal vaccine R&D. Nevertheless, few mucosal vaccines have reached the marketplace and products are still treated with caution, particularly where live organisms are utilized. In this review, we examine the use of delivery systems with adjuvant properties as key components in a vaccine strategy that does not require the use of live vectors to overcome tolerance and have exemplified their success in mucosal vaccines, concentrating on the nasal and oral routes of administration.
LanguageEnglish
Pages103-112
Number of pages9
JournalExpert Review of Vaccines
Volume8
Issue number1
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Vaccines
Nose
Oral Administration
Antigens

Keywords

  • adjuvant
  • delivery system
  • mucosal immunization
  • tolerance
  • vaccine

Cite this

Ferro, V.A. ; Mann, J.F.S. ; Acevedo, R. ; del Campo, J. ; Pere, O. / Delivery systems: a vaccine strategy for overcoming mucosal tolerance?. In: Expert Review of Vaccines. 2009 ; Vol. 8, No. 1. pp. 103-112.
@article{a390df227fef4ac696907c18c7bd35e0,
title = "Delivery systems: a vaccine strategy for overcoming mucosal tolerance?",
abstract = "Antigens administered via the oral and, to a lesser extent, the nasal route are potentially able to invoke tolerance, resulting in a nonreactive immune response. This has been a hurdle for mucosal vaccine development and yet the desire to induce protective local and systemic responses, with pain-free and more convenient products, has been the impetus driving mucosal vaccine R&D. Nevertheless, few mucosal vaccines have reached the marketplace and products are still treated with caution, particularly where live organisms are utilized. In this review, we examine the use of delivery systems with adjuvant properties as key components in a vaccine strategy that does not require the use of live vectors to overcome tolerance and have exemplified their success in mucosal vaccines, concentrating on the nasal and oral routes of administration.",
keywords = "adjuvant, delivery system, mucosal immunization, tolerance, vaccine",
author = "V.A. Ferro and J.F.S. Mann and R. Acevedo and {del Campo}, J. and O. Pere",
year = "2009",
month = "1",
doi = "10.1586/14760584.8.1.103",
language = "English",
volume = "8",
pages = "103--112",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
number = "1",

}

Delivery systems: a vaccine strategy for overcoming mucosal tolerance? / Ferro, V.A.; Mann, J.F.S.; Acevedo, R.; del Campo, J.; Pere, O.

In: Expert Review of Vaccines, Vol. 8, No. 1, 01.2009, p. 103-112.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Delivery systems: a vaccine strategy for overcoming mucosal tolerance?

AU - Ferro, V.A.

AU - Mann, J.F.S.

AU - Acevedo, R.

AU - del Campo, J.

AU - Pere, O.

PY - 2009/1

Y1 - 2009/1

N2 - Antigens administered via the oral and, to a lesser extent, the nasal route are potentially able to invoke tolerance, resulting in a nonreactive immune response. This has been a hurdle for mucosal vaccine development and yet the desire to induce protective local and systemic responses, with pain-free and more convenient products, has been the impetus driving mucosal vaccine R&D. Nevertheless, few mucosal vaccines have reached the marketplace and products are still treated with caution, particularly where live organisms are utilized. In this review, we examine the use of delivery systems with adjuvant properties as key components in a vaccine strategy that does not require the use of live vectors to overcome tolerance and have exemplified their success in mucosal vaccines, concentrating on the nasal and oral routes of administration.

AB - Antigens administered via the oral and, to a lesser extent, the nasal route are potentially able to invoke tolerance, resulting in a nonreactive immune response. This has been a hurdle for mucosal vaccine development and yet the desire to induce protective local and systemic responses, with pain-free and more convenient products, has been the impetus driving mucosal vaccine R&D. Nevertheless, few mucosal vaccines have reached the marketplace and products are still treated with caution, particularly where live organisms are utilized. In this review, we examine the use of delivery systems with adjuvant properties as key components in a vaccine strategy that does not require the use of live vectors to overcome tolerance and have exemplified their success in mucosal vaccines, concentrating on the nasal and oral routes of administration.

KW - adjuvant

KW - delivery system

KW - mucosal immunization

KW - tolerance

KW - vaccine

UR - http://dx.doi.org/10.1586/14760584.8.1.103

U2 - 10.1586/14760584.8.1.103

DO - 10.1586/14760584.8.1.103

M3 - Article

VL - 8

SP - 103

EP - 112

JO - Expert Review of Vaccines

T2 - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 1

ER -